Form 4: Veracyte Director Karin Eastham Sells 7,500 Shares Under 10b5-1 Plan

Karin Eastham, a director at Veracyte, Inc., sold 7,500 shares of common stock at $25 per share on July 16, 2024, according to a Form 4 filing with the SEC.

Summary

• On July 16, 2024, Karin Eastham, a director of Veracyte, Inc. (VCYT), sold 7,500 shares of the company's common stock.
• The sale was executed at a price of $25 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted by Eastham on March 8, 2024.
• Following the transaction, Eastham directly owns 33,228 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any inside information.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder confidence, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates